Contrasting Global Future City (OTCMKTS:FTCY) & Ovid Therapeutics (NASDAQ:OVID)

Global Future City (OTCMKTS:FTCY) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation and Earnings

This table compares Global Future City and Ovid Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Future City	N/A	N/A	N/A	N/A	N/A
Ovid Therapeutics	$548,000.00	37.61	-$52.34 million	($0.35)	-0.83

Global Future City has higher earnings, but lower revenue than Ovid Therapeutics.

Volatility & Risk

Global Future City has a beta of -0.61, suggesting that its share price is 161% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500.

Profitability

This table compares Global Future City and Ovid Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Future City	N/A	N/A	N/A
Ovid Therapeutics	-5,142.56%	-39.24%	-26.19%

Institutional & Insider Ownership

72.2% of Ovid Therapeutics shares are owned by institutional investors. 13.3% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Global Future City and Ovid Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Future City	0	0	0	0	0.00
Ovid Therapeutics	0	1	5	1	3.00

Ovid Therapeutics has a consensus price target of $3.03, suggesting a potential upside of 946.70%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Ovid Therapeutics is more favorable than Global Future City.

Summary

Ovid Therapeutics beats Global Future City on 8 of the 11 factors compared between the two stocks.

About Global Future City

Global Future City Holding, Inc. is an holding company. It focused in the areas of consumer product sales and EB-5 investments. The company was founded on October 12, 2000 and is headquartered in Irvine, CA.

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.